Cipla, on Monday, said it planned to invest up to 100 million pound in its U.K. subsidiary over the next few years.
“The investment will fund the launch of a range of drugs in the areas of respiratory, oncology and antiretroviral medicines as well as research and development, clinical trials and further expansion internationally and in the U.K., a statement from the company said.
“On the occasion of the 66th anniversary of the British National Health Service (NHS), Cipla believes that by providing high quality affordable medicines for patients, it can contribute cost effective solutions for the NHS,’’ Rajesh Garg, Global Chief Financial Officer and member of the board of Cipla said in a statement.
